Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: A case report and review of the literature

Hye Won Lee, Moon Jae Chung, Huapyong Kang, Heun Choi, Youn Jeong Choi, Kyung Joo Lee, Seung Woo Lee, Seung Hyuk Han, Jin Seok Kim, Si Young Song

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Hemolytic uremic syndrome (HUS) is a rare thrombotic complication characterized by a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS may be caused by several different conditions, including infection, malignancy, and chemotherapeutic agents, such as mitomycin, cisplatin, and most recently, gemcitabine. The outcome of gemcitabine-induced HUS is poor, and the disease has a high mortality rate. This study reports a case of gemcitabine-induced HUS in a patient with pancreatic cancer in Korea.

Original languageEnglish
Pages (from-to)109-112
Number of pages4
JournalGut and liver
Volume8
Issue number1
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

gemcitabine
Hemolytic-Uremic Syndrome
Pancreatic Neoplasms
Hemolytic Anemia
Mitomycin
Korea
Acute Kidney Injury
Thrombocytopenia
Cisplatin
Mortality
Infection
Neoplasms

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Lee, H. W., Chung, M. J., Kang, H., Choi, H., Choi, Y. J., Lee, K. J., ... Song, S. Y. (2014). Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: A case report and review of the literature. Gut and liver, 8(1), 109-112. https://doi.org/10.5009/gnl.2014.8.1.109
Lee, Hye Won ; Chung, Moon Jae ; Kang, Huapyong ; Choi, Heun ; Choi, Youn Jeong ; Lee, Kyung Joo ; Lee, Seung Woo ; Han, Seung Hyuk ; Kim, Jin Seok ; Song, Si Young. / Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer : A case report and review of the literature. In: Gut and liver. 2014 ; Vol. 8, No. 1. pp. 109-112.
@article{dda8c341513f417490e2a55b63836bac,
title = "Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: A case report and review of the literature",
abstract = "Hemolytic uremic syndrome (HUS) is a rare thrombotic complication characterized by a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS may be caused by several different conditions, including infection, malignancy, and chemotherapeutic agents, such as mitomycin, cisplatin, and most recently, gemcitabine. The outcome of gemcitabine-induced HUS is poor, and the disease has a high mortality rate. This study reports a case of gemcitabine-induced HUS in a patient with pancreatic cancer in Korea.",
author = "Lee, {Hye Won} and Chung, {Moon Jae} and Huapyong Kang and Heun Choi and Choi, {Youn Jeong} and Lee, {Kyung Joo} and Lee, {Seung Woo} and Han, {Seung Hyuk} and Kim, {Jin Seok} and Song, {Si Young}",
year = "2014",
month = "1",
day = "1",
doi = "10.5009/gnl.2014.8.1.109",
language = "English",
volume = "8",
pages = "109--112",
journal = "Gut and Liver",
issn = "1976-2283",
publisher = "Joe Bok Chung",
number = "1",

}

Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer : A case report and review of the literature. / Lee, Hye Won; Chung, Moon Jae; Kang, Huapyong; Choi, Heun; Choi, Youn Jeong; Lee, Kyung Joo; Lee, Seung Woo; Han, Seung Hyuk; Kim, Jin Seok; Song, Si Young.

In: Gut and liver, Vol. 8, No. 1, 01.01.2014, p. 109-112.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer

T2 - A case report and review of the literature

AU - Lee, Hye Won

AU - Chung, Moon Jae

AU - Kang, Huapyong

AU - Choi, Heun

AU - Choi, Youn Jeong

AU - Lee, Kyung Joo

AU - Lee, Seung Woo

AU - Han, Seung Hyuk

AU - Kim, Jin Seok

AU - Song, Si Young

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Hemolytic uremic syndrome (HUS) is a rare thrombotic complication characterized by a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS may be caused by several different conditions, including infection, malignancy, and chemotherapeutic agents, such as mitomycin, cisplatin, and most recently, gemcitabine. The outcome of gemcitabine-induced HUS is poor, and the disease has a high mortality rate. This study reports a case of gemcitabine-induced HUS in a patient with pancreatic cancer in Korea.

AB - Hemolytic uremic syndrome (HUS) is a rare thrombotic complication characterized by a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS may be caused by several different conditions, including infection, malignancy, and chemotherapeutic agents, such as mitomycin, cisplatin, and most recently, gemcitabine. The outcome of gemcitabine-induced HUS is poor, and the disease has a high mortality rate. This study reports a case of gemcitabine-induced HUS in a patient with pancreatic cancer in Korea.

UR - http://www.scopus.com/inward/record.url?scp=84893052376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893052376&partnerID=8YFLogxK

U2 - 10.5009/gnl.2014.8.1.109

DO - 10.5009/gnl.2014.8.1.109

M3 - Article

C2 - 24516709

AN - SCOPUS:84893052376

VL - 8

SP - 109

EP - 112

JO - Gut and Liver

JF - Gut and Liver

SN - 1976-2283

IS - 1

ER -